InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Friday morning. The firm issued a sell rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Down 0.4 %

NYSE:NSPR opened at $2.45 on Friday. The stock has a market capitalization of $61.08 million, a price-to-earnings ratio of -3.22 and a beta of 0.91. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.77. The firm has a 50 day moving average of $2.69 and a 200 day moving average of $2.56.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter in the prior year, the company posted ($0.24) EPS. As a group, analysts expect that InspireMD will post -0.82 EPS for the current year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC bought a new position in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD at the end of the most recent reporting period. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.